Effect of vildagliptin on hepatic steatosis. - Wikidata - awgldk - TriplyDB

Effect of vildagliptin on hepatic steatosis.

Effect of vildagliptin on hepatic steatosis.

http://www.wikidata.org/entity/Q35442079

about

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Altered volume, morphology and composition of the pancreas in type 2 diabetes.Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.Non-alcoholic fatty liver disease and diabetes.Linagliptin alleviates fatty liver disease in diabetic db/db mice Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease.Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients Gliptins and cardiometabolic risk.Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes.Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5).Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in Type 2 diabetes.Drug therapy for ectopic fat: myth or reality?Vildagliptin Can Alleviate Endoplasmic Reticulum Stress in the Liver Induced by a High Fat Diet.Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies.

P2860

Q26751258-DC8E62A1-82BE-4257-971D-0BC6374B4120 Q30846870-56095976-EF73-4713-911D-50C996215C55 Q33802278-5259985D-1B44-4C7D-997E-199D3381288C Q35623969-EC9E3322-C74D-4A63-8ABF-7031CD5E79DA Q35916947-3DD65CFF-9D83-492A-BC4E-42101174F74D Q35928257-C28E2B75-9196-47A5-A3E9-974B11951C05 Q37024780-DC847CC6-04DC-4F69-AC5C-2FB50B2BE768 Q37091659-F99FA123-FED3-4D6A-8ACC-4559C834472E Q37411528-5A88DF7A-9973-4204-B1AA-8CDE28A0A3F9 Q37563114-15947366-9A48-4741-910D-3151CAE5117A Q38620945-F9BB6CA7-1421-46AB-BC4F-36B776623C28 Q38682317-6F189434-5E61-46CB-9058-B1198DFC7B73 Q38778064-91D0B188-69E6-4D7D-AFCF-72F6468F3A81 Q39170225-5AAAE1AA-4CE1-424D-8061-B68C49D6D688 Q39717289-BFB58E59-E51F-423C-88BF-66325533CD62 Q40422340-4AD7F8D6-7A52-4123-835E-CFAB55C2CE1C Q40581820-0DE7F4EC-3B4D-4B87-8568-93C9E48D7843 Q41844464-0E972496-4FBF-4C27-B0EE-72B19D297970 Q46357255-C5F478AA-606B-4B1B-8284-FEBF98F96957 Q48152092-626BFA20-E9DE-4861-9A3C-E8FBB8ACFC22 Q50259673-DC2948B9-02CB-4AA2-8C8F-87A009FB6A1C Q53707823-436C1272-51E5-45E8-AF6B-5FC80416314D Q55253186-448A59D8-55AF-4CBA-B0D3-C2B0B4930712 Q55512053-1040FA79-E708-4BD6-85AD-E150AB009DC0

P2860

Effect of vildagliptin on hepatic steatosis.

http://www.wikidata.org/entity/Q35442079

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Effect of vildagliptin on hepatic steatosis.

@ast

Effect of vildagliptin on hepatic steatosis.

@en

type

label

Effect of vildagliptin on hepatic steatosis.

@ast

Effect of vildagliptin on hepatic steatosis.

@en

prefLabel

Effect of vildagliptin on hepatic steatosis.

@ast

Effect of vildagliptin on hepatic steatosis.

@en

P1433

Q35442079-5B418B6E-9E6E-4070-9F95-E4B542143828

P1476

Q35442079-705461FF-5149-4E8F-9F8F-266532ECA0F8

P2093

Q35442079-0ED9946F-0EE2-4F17-BECA-FE9C3B76949A

Q35442079-475F6713-A2F6-402E-B8C7-C2F91BB81AE6

Q35442079-5E0A7690-432F-4769-93C0-900359B946E8

Q35442079-74D52A25-F9B6-4A45-9554-DF0B804A64A7

Q35442079-9B1105CC-B73C-4B10-A552-A84C45265F15

Q35442079-AB6D45C0-F6A2-4152-9C01-420C87C99599

Q35442079-DBCD20CC-38B1-456E-A732-872CBE580D4F

Q35442079-EE99812D-776C-4CC4-9034-A5893A129BB3

P2860

Q35442079-13741DC8-1382-44AB-9325-4C2AA32E1C01

Q35442079-220729B8-5F51-426D-BAB8-103A5A80EA06

Q35442079-2347EA0C-0B6B-4764-ABE6-706BD906FB62

Q35442079-26443B47-737A-484C-97A0-110FB8F099B4

Q35442079-309B29F8-2ADE-45A5-82FA-B7F93937513F

Q35442079-30DB0067-C46D-4848-9928-36BF3DEADA79

Q35442079-357207ED-02F7-48B2-B672-F433B2615539

Q35442079-39A29226-687C-4E58-9361-6E201E1C8833

Q35442079-43E7CDC3-8760-4BA9-A04C-5879190A762C

Q35442079-4833097B-DDB2-46DF-B3CE-04F475C3E4EF

P304

Q35442079-5B386F7C-07C9-4848-B877-20E072942612

P31

Q35442079-02D54E67-752D-4A28-A9EA-71BA590679AB

P356

Q35442079-6FC2C639-BBC0-4796-947E-82DF785695BA

P407

Q35442079-651E377E-8D85-4F6E-8D8C-A6EE60B2BBA6

P433

Q35442079-B1BBD8F3-856B-4CAB-AF8B-67DB17A69325

P478

Q35442079-E08C4387-FE88-408B-BBE8-9FCE6B8AF774

P577

Q35442079-99AC15D4-509F-4D23-8D02-F82817DBE43C

P5875

Q35442079-E2F782C3-37EC-410C-9840-B5709BD6239E

P698

Q35442079-E81328B2-69DA-4FA6-AE43-647905E4F04E

P932

Q35442079-2F5C0806-AC14-49CE-B276-37AB36D4F4BF

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Effect of vildagliptin on hepatic steatosis.

@en

P2093

Ahmad Al-Mrabeh

http://www.w3.org/2001/XMLSchema#string

Anja Schweizer

http://www.w3.org/2001/XMLSchema#string

Fiona E Smith

http://www.w3.org/2001/XMLSchema#string

James E Foley

http://www.w3.org/2001/XMLSchema#string

Kieren G Hollingsworth

http://www.w3.org/2001/XMLSchema#string

Mavin Macauley

http://www.w3.org/2001/XMLSchema#string

Peter E Thelwall

http://www.w3.org/2001/XMLSchema#string

Roy Taylor

http://www.w3.org/2001/XMLSchema#string

P2860

Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

Three-point Dixon technique for true water/fat decomposition with B0 inhomogeneity correction.

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.

Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.

Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.

Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.

Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.

P304

1578-1585

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2014-3794

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272096873

http://www.w3.org/2001/XMLSchema#string

P698

25664602

http://www.w3.org/2001/XMLSchema#string

P932

4399299

http://www.w3.org/2001/XMLSchema#string